ライフサイエンスコーパス: viral hepatitis

1 nts can build their local strategies towards viral hepatitis.

2 chronic NALD, but not in those with chronic viral hepatitis.

3 ere stratified by the presence or absence of viral hepatitis.

4 eased in humans and chimpanzees with chronic viral hepatitis.

5 target cells for future treatment options in viral hepatitis.

6 inant IFN-alpha for the treatment of chronic viral hepatitis.

7 it contributes to the pathogenesis of acute viral hepatitis.

8 (HCV), this has not been evaluated in acute viral hepatitis.

9 was critical for priming T cell responses in viral hepatitis.

10 ponents of the liver parenchyma during acute viral hepatitis.

11 tor and a hepatoprotective cytokine in acute viral hepatitis.

12 lications of these effects as they relate to viral hepatitis.

13 therapeutic candidate for the management of viral hepatitis.

14 temporally restricted to the acute phase of viral hepatitis.

15 mmune responses to viral antigens in chronic viral hepatitis.

16 osis in the early and intermediate stages of viral hepatitis.

17 pffer cells and hepatocytes of patients with viral hepatitis.

18 targets for this most severe form of chronic viral hepatitis.

19 clinical features are compatible with acute viral hepatitis.

20 ) to those from source patients with chronic viral hepatitis.

21 e (ALT) activity among 11,821 adults without viral hepatitis.

22 have great therapeutic potential in chronic viral hepatitis.

23 reviously been correlated with resistance to viral hepatitis.

24 eck and epidemic infection, including recent viral hepatitis.

25 st hepatitis C virus (HCV), a major cause of viral hepatitis.

26 year will help us fine tune the treatment of viral hepatitis.

27 lly all of the liver disease associated with viral hepatitis.

28 nce of liver infections, such as malaria and viral hepatitis.

29 to-date summary of important developments in viral hepatitis.

30 cal and histopathological changes typical of viral hepatitis.

31 s) and organ damage in mouse models of acute viral hepatitis.

32 account for over 75% of the global burden of viral hepatitis.

33 orld Health Organization plan of eliminating viral hepatitis.

34 s the numbers of adult migrants screened for viral hepatitis.

35 patitis D is the most severe form of chronic viral hepatitis.

36 r other diseases, including tuberculosis and viral hepatitis.

37 of excess alcohol consumption, obesity, and viral hepatitis.

38 fection typically causes self-limiting acute viral hepatitis.

39 ical features resembling those seen in human viral hepatitis.

40 s (HDV) causes the most severe form of human viral hepatitis.

41 liver disease, hepatocellular carcinoma, and viral hepatitis.

42 delta virus (HDV) is the most severe form of viral hepatitis.

43 tocellular carcinoma with or without chronic viral hepatitis.

44 rated the potential for the immunotherapy of viral hepatitis.

45 or the most severe form of acute and chronic viral hepatitis.

46 thologies such as cholestasis, steatosis and viral hepatitis.

47 on diagnoses were latent tuberculosis (22%), viral hepatitis (17%), active tuberculosis (10%), human

48 0 with acetaminophen-related injury, 26 with viral hepatitis, 19 with ischemic injury, and 62 others.

49 non-acetaminophen drug-induced (26.1%), and viral hepatitis (2.5%).

50 e draft WHO Global Health Sector Strategy on Viral Hepatitis 2016-21 provides a solid framework upon

51 SL metabolites in 406 patients with chronic viral hepatitis, 203 infected with genotype 1 hepatitis

52 276 patients with chronic liver disease (42% viral hepatitis, 46% nonalcoholic fatty liver disease [N

53 eatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO me

54 a variety of other causes, but not including viral hepatitis A through E.

55 We aimed to document the prevalence of viral hepatitis A to E in Hong Kong.

56 lies on exclusion of other causes, including viral hepatitis A, B, and C.

57 Chronic viral hepatitis accounts for >80% of liver-related morta

58 Health and Human Services (HHS) published a viral hepatitis action plan that guides response to the

59 Viral hepatitis affects millions of people worldwide, ma

60 Studies on viral hepatitis after liver transplantation again focuse

61 rs indicate the need for improved control of viral hepatitis after solid organ transplantation.

62 nding preexisting liver illnesses, including viral hepatitis, alcohol abuse, or metabolic disease.

63 mortality from extrahepatic complications of viral hepatitis, alcoholic liver disease (ALD), and nona

64 virus, generally causes self-limiting acute viral hepatitis, although chronic HEV infection has rece

65 es histological features with those of human viral hepatitis, although the specific aetiological agen

66 rovements in vaccines and treatments against viral hepatitis, an improved understanding of the burden

67 Chronic viral hepatitis and alcohol remain leading causes of cir

68 ound of chronic liver inflammation caused by viral hepatitis and alcoholic or nonalcoholic steatohepa

69 Furthermore, the contributions of viral hepatitis and ALD to CLD mortality may be underest

70 al mechanism for the death of hepatocytes in viral hepatitis and also in endothelial injury in the co

71 Only viral hepatitis and arterial hypertension were independe

72 asive screening for HCC in populations where viral hepatitis and cirrhosis are prevalent.

73 his study describes the relationship between viral hepatitis and HCC in New York City (NYC).

74 n the United States, experts in the field of viral hepatitis and liver and kidney transplantation con

75 ated in clinical trials for the treatment of viral hepatitis and liver cancer.

76 is widely used for the treatment of chronic viral hepatitis and malignancies.

77 nic liver disease are excess alcohol intake, viral hepatitis and non-alcoholic fatty liver disease, w

78 AdCre developed a relatively mild course of viral hepatitis and recovered spontaneously.

79 e morbidity and mortality related to chronic viral hepatitis and released its findings in a report.

80 sion of the stop cassette led to a transient viral hepatitis and resulted in multinodular tumorigenes

81 vices can increase the success of preventing viral hepatitis and the effectiveness of hepatitis treat

82 ay an important role in both defense against viral hepatitis and the pathogenesis of other liver dise

83 V and other infectious complications such as viral hepatitis and tuberculosis, and many non-HIV-assoc

84 oners (GPs) were given a teaching session on viral hepatitis and were asked to test all registered mi

85 idity and mortality worldwide due to chronic viral hepatitis and, more recently, from fatty liver dis

86 While increases in overdoses, viral hepatitis, and endocarditis associated with drug u

87 nsplant immunology, infection, inflammation, viral hepatitis, and fibrogenesis.

88 esponsible for severe diseases such as AIDS, viral hepatitis, and flu.

89 o estimate morbidity and mortality for acute viral hepatitis, and for cirrhosis and liver cancer caus

90 liver diagnoses (eg, hepatorenal syndrome), viral hepatitis, and hepatobiliary cancers.

91 is, opioid use, HIV, psychoactive drugs use, viral hepatitis, and obesity, each with more than two-th

92 in the livers of patients with autoimmune or viral hepatitis, and of mice during concanavalin A (Con

93 Viral hepatitis, and particularly hepatitis B virus (HBV

94 f its comorbidities, including tuberculosis, viral hepatitis, and renal and cardiovascular disease.

95 s include gallstones, hepatic sequestration, viral hepatitis, and sickle cell intrahepatic cholestasi

96 have a lack of knowledge and awareness about viral hepatitis, and that there is a gap between medical

97 The enormous health loss attributable to viral hepatitis, and the availability of effective vacci

98 a range of infectious diseases such as HIV, viral hepatitis, and tuberculosis.

99 es, for the prevention and treatment of HIV, viral hepatitis, and tuberculosis.

100 discrimination against people infected with viral hepatitis; and financial barriers to treatment and

101 nch National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO13 HEPAVIH cohort initiating an

102 ated liver diseases including autoimmune and viral hepatitis are a major health problem worldwide.

103 FPAs during acute viral hepatitis are associated with higher IgM levels an

104 HIV and viral hepatitis are independently associated with an inc

105 f persons at risk for or who are living with viral hepatitis are not aware of the risks, have not bee

106 rld Health Assembly calls for elimination of viral hepatitis as a public health threat by 2030 (ie, -

107 first global strategy towards elimination of viral hepatitis as a public health threat by 2030, the p

108 The majority of the patients had viral hepatitis as the underlying liver disease (100% in

109 is virus, a murine coronavirus used to model viral hepatitis as well as other human diseases.

110 ntrol group, 17 patients tested positive for viral hepatitis, as did 220 patients (one with a co-infe

111 gic evaluation revealed no evidence of acute viral hepatitis, autoimmune, metabolic or alcohol-relate

112 ubjects died from cirrhosis; 33 of them from viral hepatitis B (29%), two from hepatitis C (2%), and

113 Data on viral hepatitis B (HBV) testing and vaccination in prima

114 527 adult participants who were negative for viral hepatitis B and C and iron overload.

115 Viral hepatitis B and C are among the most common causes

116 osis and management of patients with chronic viral hepatitis B and C depend on the amount and progres

117 1988-1994, who were negative for markers of viral hepatitis B and C.

118 Randomisation was stratified by viral hepatitis B or C coinfection and computer-generate

119 been implicated in protecting patients with viral hepatitis B or C from developing hepatocellular ca

120 methods used to manage patients with chronic viral hepatitis B or C infection.

121 elopments in the treatment and prevention of viral hepatitis based on publications between December 2

122 eview of recent developments in the field of viral hepatitis, based on publications between December

123 eview of recent developments in the field of viral hepatitis, based on publications between December

124 eview of recent developments in the field of viral hepatitis, based on publications between December

125 ll highlight mother-to-child transmission of viral hepatitis, both management and public health impli

126 s, and liver fibrosis in those infected with viral hepatitis (Buch et al., 2015; Mancina et al., 2016

127 HO adopted a strategy for the elimination of viral hepatitis by 2030.

128 and for cirrhosis and liver cancer caused by viral hepatitis, by age, sex, and country from 1990 to 2

129 e of antiviral treatment options for chronic viral hepatitis C (CHC), shared clinical decision-making

130 Viral hepatitis C (HCV), a small (+)-RNA virus, infects

131 Pathologic features of viral hepatitis C and E, immunohistochemistry for the du

132 miR-122, a pro-viral hepatitis C virus (HCV) host factor, binds and rec

133 ibrosis extent, including cause of fibrosis (viral hepatitis C vs nonalcoholic fatty liver disease, P

134 operational interventions along the chronic viral hepatitis care continuum, published in English up

135 e engagement and retention along the chronic viral hepatitis care continuum.

136 Viral hepatitis cases reported to the NYC Department of

137 idespread use of DAA agents for treatment of viral hepatitis, cause-specific mortality from extrahepa

138 During development of chronic viral hepatitis, CCL5 and CXCL10 regulate the cytopathic

139 Division of Viral Hepatitis, Centers for Disease Control and Prevent

140 ic steatohepatitis, alcoholic liver disease, viral hepatitis, cholangiopathies, and hepatobiliary mal

141 iver disease, non-alcoholic steatohepatitis, viral hepatitis, cholestatic liver disease and autoimmun

142 on people worldwide, is the leading cause of viral hepatitis, cirrhosis and hepatocellular carcinoma.

143 nch National Agency for Research on Aids and Viral Hepatitis CO13 HEPAVIH cohort (983 patients, 4,432

144 nch National Agency for Research on AIDS and Viral Hepatitis CO13 HEPAVIH cohort.

145 In a nationwide viral hepatitis cohort, lipophilic statins were associat

146 ral hepatitis monoinfected (n = 74), and HIV-viral hepatitis coinfected (n = 66).

147 Among the HIV-infected men, viral hepatitis coinfection (2.34-FI; P < .001), HIV RNA

148 icity, ART usually is safe for patients with viral hepatitis coinfection, and, in some cases, treatme

149 tients were included, all of them related to viral hepatitis coinfection: hepatitis C virus (HCV) in

150 Etiologies of liver disease include viral hepatitis coinfections, drug-related hepatotoxicit

151 Viral hepatitis constitutes the most common entity seen

152 uses were initially thought to cause non-A-G viral hepatitis, continued research has shown no definit

153 The WHO global health sector strategy on viral hepatitis, created in May, 2016, aims to achieve a

154 Between 1990 and 2013, global viral hepatitis deaths increased from 0.89 million (95%

155 Chronic viral hepatitis depends on the inability of the T-cell i

156 Other major advances in the field of viral hepatitis during the past year are highlighted.

157 nject drugs receive services, and a national viral hepatitis education campaign that targets health c

158 should be taken as an opportunity to achieve viral hepatitis elimination targets, by establishing a w

159 Children without viral hepatitis enrolled in 2 trials for stroke preventi

160 itis action plan that guides response to the viral hepatitis epidemic by providing explicit steps to

161 Viral hepatitis epidemiological data are important for t

162 substantial portion of the global burden of viral hepatitis, especially chronic hepatitis B and hepa

163 usions were baseline clinical liver disease, viral hepatitis, ethanol intake >50 g/day, and current a

164 chronic liver disease (n = 1037), defined as viral hepatitis, excessive alcohol consumption, or incre

165 efore peer-review, creating confusion in the viral hepatitis field.

166 Recurrent viral hepatitis following liver transplantation may limi

167 to the Italian Surveillance System for Acute Viral Hepatitis from 1993 to 2014.

168 Fulminant viral hepatitis (FVH) is a devastating and unexplained c

169 irus (HEV) is the most common cause of acute viral hepatitis globally.

170 the leading cause of enterically transmitted viral hepatitis globally.

171 To compare the chronic viral hepatitis group and the NALD group, we used t-test

172 me from onset of injection to acquisition of viral hepatitis has increased, we also compared the find

173 Up to 30% of acute viral hepatitis has no known etiology.

174 However, the involvement of complement in viral hepatitis has not been well documented.

175 New insights into the management of viral hepatitis have been gained over the past year.

176 iral hepatitis, sorafenib progressor without viral hepatitis, HCV infected, and HBV infected.

177 lcoholic fatty liver disease, and/or chronic viral hepatitis (hepatitis B and C), results in damage t

178 Chronic viral hepatitis (hepatitis B and hepatitis C) infection

179 The prevalence of viral hepatitis (hepatitis B virus and hepatitis C virus

180 al therapies will not decrease the burden of viral hepatitis if persons at risk for or who are living

181 In 2015, the Coalition to Eradicate Viral Hepatitis in Asia Pacific gathered leading hepatit

182 s associated with endemic and epidemic acute viral hepatitis in developing countries.

183 sative agent of hepatitis E, a major form of viral hepatitis in developing countries.

184 9 may have therapeutic value against chronic viral hepatitis in human patients.

185 s leading to the most severe form of chronic viral hepatitis in man.

186 e assays to identify biomarker signatures of viral hepatitis in order to define unique and common res

187 king at means of prevention and treatment of viral hepatitis in patients undergoing liver transplanta

188 itis E virus (HEV) is a major cause of acute viral hepatitis in people in many developing countries a

189 Screening migrants for viral hepatitis in primary care is effective if doctors

190 a nationwide study of patients with chronic viral hepatitis in Sweden, use of low-dose aspirin was a

191 eligible for testing and tested positive for viral hepatitis in the intervention groups were eligible

192 ted to assess the clinical impact of chronic viral hepatitis in the United States.

193 irus (HEV) is the most common cause of acute viral hepatitis in the world.

194 particularly relevant for the development of viral hepatitis, in which both the sensitivity of hepato

195 viremia presented characteristics typical of viral hepatitis, including viral RNA and proteins in hep

196 es, the absolute burden and relative rank of viral hepatitis increased between 1990 and 2013.

197 In the setting of viral hepatitis, increased expression of Gal-9 drives th

198 Viral hepatitis-induced oxidative stress accompanied by

199 fection (1.39-fold increase [FI]; P < .001), viral hepatitis infection (1.52-FI; P < .001), and the i

200 Viral hepatitis infection is a primary risk factor for H

201 Viral hepatitis infection, which is a major cause of liv

202 that the association may differ by status of viral hepatitis infection.

203 th HCC have viral hepatitis; the majority of viral hepatitis infections are due to HCV.

204 ngthy follow-up, only a fraction of expected viral hepatitis infections were identified.

205 < .001), and the interaction between HIV and viral hepatitis infections were independently associated

206 ytic function and cytokine production in all viral hepatitis infections: Hepatitis virus infections d

207 s has been implicated in the pathogenesis of viral hepatitis, insulin resistance, hepatosteatosis, an

208 88-1994, with excessive alcohol consumption, viral hepatitis, iron overload, overweight, or impaired

209 Viral hepatitis is a leading cause of death and disabili

210 Tissue damage caused by viral hepatitis is a major cause of morbidity and mortal

211 Viral hepatitis is a major public health threat and a le

212 rch indicates that the mortality burden from viral hepatitis is growing, particularly among middle-ag

213 Screening for viral hepatitis is important in individuals diagnosed as

214 , an improved understanding of the burden of viral hepatitis is needed to inform global intervention

215 Annual mortality from viral hepatitis is similar to that of other major infect

216 Viral hepatitis is still one of the most common causes o

217 Worldwide, viral hepatitis is the leading cause of acute liver fail

218 Viral hepatitis is the leading cause of liver disease wo

219 Viral hepatitis is the most common form of hepatitis and

220 of liver diseases as diverse as cholestasis, viral hepatitis, ischemia/reperfusion, liver preservatio

221 Although PG has also been reported with viral hepatitis, it is rarely associated with autoimmune

222 ults in the most rapidly progressive form of viral hepatitis; it is the chronic viral infection that

223 carcity of immunocompetent animal models for viral hepatitis, little is known about the early innate

224 us (HCV), a Hepacivirus, is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular car

225 HBV is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular car

226 BV) is the major causative factor of chronic viral hepatitis, liver cirrhosis, and hepatocellular car

227 physiology and pathophysiology, focusing on viral hepatitis, liver fibrosis, and cancer.

228 ure, and the presence of co-existing chronic viral hepatitis may increase its severity.

229 ibrosis (Meta-Analysis of Histologic Data in Viral Hepatitis [METAVIR] fibrosis stage F3) or cirrhosi

230 ting via the World Health Organization (WHO) viral hepatitis monitoring platform and for ensuring acc

231 cted (n = 1170), HIV monoinfected (n = 509), viral hepatitis monoinfected (n = 74), and HIV-viral hep

232 Like human viral hepatitis, murine Helicobacter hepaticus infection

233 BMI was unrelated to viral hepatitis (n = 1,477), and had a U-shaped associat

234 Liver disease was caused by viral hepatitis (n = 136), alcoholic or nonalcoholic ste

235 ients who underwent liver biopsy for chronic viral hepatitis (n=19) or other chronic non-alcoholic li

236 We studied 13,298 viral hepatitis negative adults who fasted at least 4 ho

237 Data were analyzed from 14,841 viral hepatitis-negative adult participants in the third

238 n 18-year period (through 2006) among 14,950 viral-hepatitis-negative adults.

239 ease in the setting of HIV infection include viral hepatitis, nonalcoholic fatty liver disease/nonalc

240 Fulminant viral hepatitis occurs in a very small number of infecte

241 or liver transplants for diseases other than viral hepatitis or an autoimmune disease who underwent i

242 These codes do not include viral hepatitis or consider hepatocellular carcinoma (HC

243 transferase (ALT) activity in the absence of viral hepatitis or excessive alcohol consumption is most

244 levated serum ALT activity in the absence of viral hepatitis or excessive alcohol consumption, most o

245 Among participants without viral hepatitis or excessive alcohol consumption, those

246 higher FRS among nonobese participants with viral hepatitis or excessive alcohol consumption.

247 None had prior or current viral hepatitis or excessive alcohol intake.

248 ng coincidental liver disease (most commonly viral hepatitis or gallstones) and underlying chronic li

249 Of cases for which viral hepatitis or hepatobiliary cancer was the cause of

250 ths while receiving ART, and without chronic viral hepatitis or other known causes of chronic liver d

251 nts with HIV mono-infection, without chronic viral hepatitis or other known causes of chronic liver d

252 g participants with significant alcohol use, viral hepatitis, or increased transferrin saturation, 4,

253 he substantial US health burden from chronic viral hepatitis, particularly among persons born during

254 have been mostly performed in the setting of viral hepatitis, particularly hepatitis C virus, where s

255 This study highlights the importance of viral hepatitis prevention and treatment and HCC screeni

256 d B vaccinations should be key components of viral hepatitis prevention.

257 nd B vaccination should be key components of viral hepatitis prevention.

258 Asian countries, the tuberculosis, HIV, and viral hepatitis programmes, including diagnostic service

259 val, Epstein-Barr virus (EBV) occurrence, or viral hepatitis recurrence.

260 evels are increased in patients with chronic viral hepatitis, reflecting macrophage activation.

261 ged men (mean age 59 years, male 68.9%) with viral hepatitis-related cirrhosis (85%).

262 quent causes of death among decedents with a viral hepatitis-related death.

263 Patients with curative resection of viral hepatitis-related HCC were eligible, and were stra

264 d not reduce the postoperative recurrence of viral hepatitis-related HCC.

265 Viral hepatitis remains the most common cause of liver d

266 thin the French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Preve

267 the French National Agency for HIV/AIDS and Viral Hepatitis Research 12 180 Reflate Tuberculosis tri

268 Acute viral hepatitis resulting due to hepatitis E viral infec

269 er in the intervention groups, the uptake of viral hepatitis screening (in the intention-to-treat pop

270 improved HBV vaccine coverage; and improved viral hepatitis services and access to those services.

271 Effective management for viral hepatitis should be integrated into HIV treatment

272 sets, a New World small primate, and induces viral hepatitis similar to HCV infection in humans.

273 s: sorafenib untreated or intolerant without viral hepatitis, sorafenib progressor without viral hepa

274 vival for persons with HCC differs widely by viral hepatitis status.

275 Men were categorized based on their HIV and viral hepatitis status: uninfected (n = 1170), HIV monoi

276 A comprehensive approach involving better viral hepatitis surveillance and case investigation, hea

277 ree health departments that perform enhanced viral hepatitis surveillance in New York and Oregon.

278 uency of and characteristics associated with viral hepatitis testing and infection prevalence among a

279 Little is known about viral hepatitis testing and infection prevalence among p

280 operational interventions to enhance chronic viral hepatitis testing, linkage to care, treatment upta

281 accelerates liver fibrosis in patients with viral hepatitis that cannot be fully explained by ethano

282 ysis was performed on e-mail inquiries about viral hepatitis that were submitted by health profession

283 oportion of patients who tested positive for viral hepatitis, the proportion who complied with treatm

284 In NYC, most persons with HCC have viral hepatitis; the majority of viral hepatitis infecti

285 The national viral hepatitis therapy program has significantly reduce

286 A national viral hepatitis therapy program was launched in Taiwan i

287 in therapeutic strategies for patients with viral hepatitis, there is a significant lack of novel th

288 ); however, in the subgroup of patients with viral hepatitis these correlations were no longer signif

289 afforded basic levels of protection against viral hepatitis transmission.

290 model for investigating the pathogenesis of viral hepatitis types A through E in humans.

291 Precipitating events may be viral hepatitis, typically in Asia, and drug or alcoholi

292 Patients with acute viral hepatitis underwent antibody testing for other cau

293 pioid treatment programs (OTPs) do not offer viral hepatitis (VH) or human immunodeficiency virus (HI

294 ration, The Global Health Sector Strategy on Viral Hepatitis was adopted by WHO.

295 Infection with viral hepatitis was associated with increased frequencie

296 In 2013, viral hepatitis was the seventh (95% UI seventh to eight

297 Using a mouse model of viral hepatitis, we identified virus-induced early trans

298 of the patients had underlying cirrhosis or viral hepatitis, which is commonly seen in adults with H

299 Livers from patients with viral hepatitis without and with HCC (n = 114) were exam

300 E in humans and the leading cause for acute viral hepatitis worldwide.